1. Home
  2. ENTA vs GLAD Comparison

ENTA vs GLAD Comparison

Compare ENTA & GLAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$14.04

Market Cap

486.3M

Sector

Health Care

ML Signal

HOLD

Logo Gladstone Capital Corporation

GLAD

Gladstone Capital Corporation

HOLD

Current Price

$18.79

Market Cap

468.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
GLAD
Founded
1995
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
486.3M
468.1M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ENTA
GLAD
Price
$14.04
$18.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$20.40
$22.33
AVG Volume (30 Days)
220.0K
203.6K
Earning Date
02-09-2026
02-04-2026
Dividend Yield
N/A
9.56%
EPS Growth
N/A
N/A
EPS
N/A
1.59
Revenue
$66,980,000.00
$91,673,000.00
Revenue This Year
$0.99
$13.52
Revenue Next Year
$0.19
$8.34
P/E Ratio
N/A
$11.85
Revenue Growth
0.58
N/A
52 Week Low
$4.09
$18.58
52 Week High
$17.15
$29.54

Technical Indicators

Market Signals
Indicator
ENTA
GLAD
Relative Strength Index (RSI) 55.34 30.01
Support Level $13.18 $18.65
Resistance Level $15.55 $19.14
Average True Range (ATR) 0.66 0.46
MACD 0.17 -0.19
Stochastic Oscillator 50.00 6.73

Price Performance

Historical Comparison
ENTA
GLAD

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About GLAD Gladstone Capital Corporation

Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.

Share on Social Networks: